Below figure shows blood glucose levels after ingestion, at the arrow of 100 grams of glucose in a patient newly diagnosed with Type II diabetes. The curve labeled R is the patient's reference response. After curve R was obtained, the patient commenced a daily exercise regime. After several weeks of exercise a second curve was obtained. Which of the following best describes the response to glucose after exercise training?
Answer(s): B
Exercise recruits both non-insulin-dependent and insulin-dependent glucose transport proteins to the plasma membrane of active skeletal muscle cells. This effectively increases sensitivity to insulin and the response to ingested glucose is blunted after exercise training. This excludes choice E, which states that no effect can be expected from exercise and choice A (curve 1), which represents a state of lower insulin receptor sensitivity compared to the sedentary state R. Ingestion of glucose will cause an initial rise of blood glucose in both active and sedentary people (excludes choices C and D).
A deficiency of argininosuccinate synthetase (ASD) can be suspected in a 2448-hour-old neonate with elevated serum ammonia. To discriminate the fact that the hyperammonemia is indeed due to ASD and not due to a deficiency in other urea cycle enzymes, one can assay for the serum concentration of citrulline and urinary orotic acid concentration. Which of the following would best describe the expected findings?
Answer(s): D
A urea cycle disorder (UCD) is likely in a neonate that has elevated serum ammonia appearing, not before, but between 24 and 48 hours after a normal term delivery. There are three hallmark symptoms associated with UCDs. These are hyperammonemia, encephalopathy, and respiratory alkalosis. Thus, elevated serum ammonia is not, in and of itself, indicative of a specific defect in the urea cycle. An analysis of the levels of various amino and organic acids in the plasma and urine is the primary key to determining which defect led to the elevation in serum ammonia. Differential diagnosis of neonatal hyperammonemia, as a consequence of a UCD can be accomplished by measurement of plasma citrulline and urinary orotic acid levels. Shown in below figure is the standard differential diagnosis chart for determining which of four possible neonatal UCDs is the cause of the hyperammonemia.First, the hyperammonemia appears in the absence of any significant acidosis or ketosis. If analysis of serum citrulline demonstrates that it is >1000 M it is confirmation that the clinical symptoms are due to a deficiency in ASD. In this circumstance it is not necessary to assay for levels of urinary orotic acid but they would be expected to be normal. Since citrulline levels are dramatically elevated in cases of ASD, choices A, B, and C are not correct.
A 7-year-old boy is examined by his pediatrician because of complaints of severe cramping pain in his legs whenever he rides his bike. He also expriences nausea and vomiting during these attacks. The child has noted that the severity of the cramps is most intense after dinners that include baked potatoes or pasta, and sometimes bread. Clinical studies undertaken following a treadmill test demonstrate myoglobinuria, hyperuricemia, and increased serum bilirubin. Which of the following enzyme deficiencies is associated with these clinical findings?
A deficiency in muscle phosphofructokinase results in glycogen storage disease type VII (Tarui disease).Clinically, the symptoms seen in Tarui disease are very similar to those seen in muscle phosphorylase deficiency (choice E), glycogen storage disease type V (McArdle disease) such as exercise-induced cramping and early fatigue. There are five clinical characteristics allowing distinction between Tarui and McArdle diseases: exercise intolerance is evident in childhood, is more severe, and is associated with nausea and vomiting; the intolerance is particularly acute following meals rich in carbohydrates; hyperuricemia is more severe; compensated hemolytic anemia is evidenced by increased serum bilirubin and reticulocyte count, and lastly; an abnormal polysaccharide is present in muscle fibers. Deficiency in glucose-6-phosphatase (choice A) is one cause of glycogen storage disease type I (specifically type Ia, von Gierke disease). Classic symptoms of this deficiency include neonatal hypoglycemia and lactic acidosis. If symptoms do not appear until the third or fourth month they include hepatomegaly and hypoglycemic seizures. Liver glycogen synthase deficiency (choice B) presents with morning fatigue and ketotic hypoglycemia on fasting--both of which rapidly disappear on feeding. Symptoms can be rapidly relieved and chemical signs corrected by introducing frequent protein-rich meals and nighttime feedings of suspensions of uncooked corn starch. Deficiency in glycogen debranching enzyme (choice C) results in glycogen storage disease type III (Cori or Forbes disease). Symptoms of type III disease are short stature, variable skeletal myopathy, cardiomyopathy, hepatomegaly, and hypoglycemia.
An adult man suffered from stable angina pectoris for 15 years, during which time there was progressive heart failure and repeated pulmonary thromboembolism. On his death at age 63, autopsy disclosed enormous cardiomyopathy (1100 g), cardiac storage of globotriaosylceramide (11 mg lipid/g wet weight), and restricted cardiocytes. Which of the following lipid storage diseases would result in these clinical findings?
Answer(s): A
Fabry disease is an X-linked disorder that results from a deficiency in alpha-galactosidase A. This leads to the deposition of neutral glycosphingolipids with terminal alpha-galactosyl moieties in most tissues and fluids. Most affected tissues are heart, kidneys, and eyes. The predominant glycosphingolipid accumulated is globotriaosylceramide [galactosyl-(14)- galactosyl-(14)-glucosyl-(11')-cer amide]. With increasing age, the major symptoms of the disease are due to increase in deposition of glycosphingolipid in the cardiovascular system. Indeed, cardiac disease occurs in most hemizygous males. Three types of Gaucher disease (choice B) have been characterized and are caused by defects in lysosomal acid beta-glucosidase (glucocerebrosidase). Defects in this enzyme lead to the accumulation of glucosylceramides (glucocerebrosides), which leads, primarily, to central nervous system (CNS) dysfunction and also hepatosplenomegaly and skeletal lesions. NPD (choice D) comprises three types of lipid storage disorder, two of which (type A and B NPD) result from a defect in acid sphingomyelinase. Type A is a disorder that leads to infantile mortality. Type B is variable in phenotype and is diagnosed by the presence of hepatosplenomegaly in childhood and progressive pulmonary infiltration. Pathologic characteristics of NPD are the accumulation of histiocytic cells that result from phingomyelin deposition in cells of the monocyte- macrophage system. Tay-Sachs disease (choice E) results from a defect in hexosaminidase A leading to the accumulation of gangliosides, particularly in neuronal cells. This defect leads to severe mental retardation, progressive weakness, and hypotonia, which prevents normal motor development. Progression of the disease is rapid and death occurs within the second year. Krabbe disease (choice C), also called globoid-cell leukodystrophy, results from a deficiency in galactosylceramidase (galactocerebroside betagalactosidase).This disease progresses rapidly and invariably leads to infantile mortality.
An investigational diabetes treatment involving a hypoglycemia-inducing drug has been developed. This drug is designed to inhibit dipeptidylpeptidase IV (DPP IV) activity and has been shown to decrease plasma glucose concentration and pancreatic glucagon secretion. DPP IV hydrolyzes which of the following hormones such that its inhibition results in the observed effects?
GLP-1 is derived from the product of the proglucagon gene. This gene encodes a preproprotein that is differentially cleaved depending on the tissue in which it is synthesized. In the gut, prohormone convertase 1/3 action leads to release of several peptides including GLP-1. On nutrient ingestion GLP- 1 is secreted from intestinal enteroendocrine Lcells. Bioactive GLP-1 consists of two forms: GLP-1(7-37) and GLP-1(7-36) amide, where the latter form constitutes the majority (80%) of the circulating hormone. The primary physiologic responses to GLP-1 are glucose-dependent insulin secretion, inhibition of glucagon secretion, and inhibition of gastric acid secretion and gastric emptying. The latter effect will lead to increased satiety with reduced food intake along with a reduced desire to ingest food. The action of GLP-1 at the level of insulin and glucagon secretion results in significant reduction in circulating levels of glucose following nutrient intake. The glucose-lowering activity of GLP-1 is highly transient as the halflife of this hormone in the circulation is less than 2 minutes. Removal of bioactive GLP-1 is a consequence of N- terminal proteolysis catalyzed by DPP IV. DPP IV is also known as the lymphocyte surface antigen CD26 and has numerous activities unrelated to hormone inactivation. Although targeting compounds that can inhibit the enzymatic action of DPP IV would seem like ideal candidates for treating the hyperglycemia of uncontrolled diabetes, there are several unknowns associated with DPP IV inhibition. One of these issues is the fact that GLP-1 is only one of the many known substrates for DPP IV cleavage. Thus, prolonged inhibition of DPP IV enzymatic activity may have unexpected consequences unrelated to control of hyperglycemiA. DPP IV is not known to hydrolyze glucagons (choice A), insulin (choice C), IGF-I (choice D), nor pancreatic polypeptide (choice E).
Post your Comments and Discuss USMLE STEP1 exam prep with other Community members:
Our website is free, but we have to fight against AI bots and content theft. We're sorry for the inconvenience caused by these security measures. You can access the rest of the STEP1 content, but please register or login to continue.